{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-035170","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.827453+00:00","generated_at":"2026-06-07T07:56:47.585605+00:00","sec_items":["5.07","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Pulse Biosciences stockholders approve equity plan amendment and ratify executive option grants","bullets":["Proposal 1 (increase share reserve by 1,375,000 shares) passed with 38.3M for, 2.97M against.","Proposal 2 (ratify options for 1,505,000 shares at $4.38) passed with 39.2M for, 2.06M against.","Ratified options include grants to CEO Kevin Danahy (460,000), Darrin Uecker (330,000), Mitchell Levinson (100,000).","Options have 10-year term, vest at 6-year anniversary or 1-year after change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-035170","json":"https://secwatch.observer/filing/0001437749-23-035170.json","markdown":"https://secwatch.observer/filing/0001437749-23-035170.md","text":"https://secwatch.observer/filing/0001437749-23-035170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923035170/0001437749-23-035170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923035170/plse20231219_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:56:47.585605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b342190b93750404895530c82b46125a0001cc15","claim":"PULSE BIOSCIENCES, INC. shareholders approved Approve amendment to 2017 Equity Incentive Plan to increase shares by 1,375,000 at the 2023-12-19 meeting.","evidence_excerpt":"Proposal 1. Amendment of the Equity Plan For Against Abstained Broker Non-votes 38,301,130 2,970,156 4,396 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923035170/0001437749-23-035170-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-19"}],"fact_type":"shareholder_vote"},{"claim_id":"d8f0c05e6a31fdd51d67018bf32ba03740b8a466","claim":"PULSE BIOSCIENCES, INC. shareholders approved Ratify options awarded on November 1, 2023 under the Equity Plan at the 2023-12-19 meeting.","evidence_excerpt":"Proposal 2. Ratification of Award For Against Abstained Broker Non-votes 39,206,759 2,064,323 4,600 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923035170/0001437749-23-035170-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-19"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}